Related Experiment Video

Updated: Aug 19, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives

J P Spano1, R Fagard, J-C Soria

  • 1SOMPS, Groupe Hospitalier Pitié-Salpétrière, Université Pierre et Marie Curie, 47 boulevard de l'Hôpital, 75013 Paris, France. jean-philippe.spano@psl.ap-hop-paris.fr

Annals of Oncology : Official Journal of the European Society for Medical Oncology
|January 26, 2005
PubMed

Insights

Epidermal growth factor receptor (EGFR) signaling drives tumor growth and is overexpressed in colorectal cancer. EGFR inhibitors may reduce tumor cell proliferation and enhance conventional therapies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Signaling

Background:

  • Epidermal growth factor receptor (EGFR) is part of the ErbB family of tyrosine kinase receptors.
  • EGFR signaling pathways are implicated in tumor growth processes.
  • EGFR overexpression is observed in colorectal cancer, but its prognostic significance is unclear.

Purpose of the Study:

  • To review the role of EGFR signaling in colorectal tumor cell survival.
  • To explore the potential of EGFR inhibitors in modulating these pathways.
  • To assess the utility of EGFR inhibitors in enhancing tumor control and treatment sensitivity.

Main Methods:

  • Literature review focusing on EGFR signaling pathways.
  • Analysis of studies on EGFR inhibitors in colorectal cancer models.
  • Examination of combination therapies involving EGFR inhibitors.

Main Results:

  • EGFR signaling actively contributes to colorectal tumor cell survival.
  • EGFR inhibitors show potential in reducing tumor cell proliferation.
  • Combination therapies (EGFR inhibitors with cytotoxic drugs or radiation) may improve outcomes.

Conclusions:

  • EGFR plays a significant role in colorectal cancer progression.
  • Targeting EGFR signaling with inhibitors offers a promising therapeutic strategy.
  • EGFR inhibitors can enhance the efficacy of conventional colorectal cancer treatments.

More Related Videos

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres06:52

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...